Anticancer effects of ikarugamycin and astemizole identified in a screen for stimulators of cellular immune responses
Background Most immunotherapies approved for clinical use rely on the use of recombinant proteins and cell-based approaches, rendering their manufacturing expensive and logistics onerous. The identification of novel small molecule immunotherapeutic agents might overcome such limitations.Method For i...
| Автори: | , , , , , , , , , , , , , , , |
|---|---|
| Формат: | Стаття |
| Мова: | English |
| Опубліковано: |
BMJ Publishing Group
2023-07-01
|
| Серія: | Journal for ImmunoTherapy of Cancer |
| Онлайн доступ: | https://jitc.bmj.com/content/11/7/e006785.full |